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Abstract
Stable isotope labeling is the state of the art technique for in vivo quantification of lympho-
cyte kinetics in humans. It has been central to a number of seminal studies, particularly in
the context of HIV-1 and leukemia. However, there is a significant discrepancy between
lymphocyte proliferation rates estimated in different studies. Notably, deuterated 2H2-glu-
cose (D2-glucose) labeling studies consistently yield higher estimates of proliferation than
deuterated water (D2O) labeling studies. This hampers our understanding of immune func-
tion and undermines our confidence in this important technique. Whether these differences
are caused by fundamental biochemical differences between the two compounds and/or by
methodological differences in the studies is unknown. D2-glucose and D2O labeling experi-
ments have never been performed by the same group under the same experimental condi-
tions; consequently a direct comparison of these two techniques has not been possible. We
sought to address this problem. We performed both in vitro and murine in vivo labeling
experiments using identical protocols with both D2-glucose and D2O. This showed that
intrinsic differences between the two compounds do not cause differences in the prolifera-
tion rate estimates, but that estimates made using D2-glucose in vivo were susceptible to
difficulties in normalization due to highly variable blood glucose enrichment. Analysis of
three published human studies made using D2-glucose and D2O confirmed this problem,
particularly in the case of short term D2-glucose labeling. Correcting for these inaccuracies
in normalization decreased proliferation rate estimates made using D2-glucose and slightly
increased estimates made using D2O; thus bringing the estimates from the two methods
significantly closer and highlighting the importance of reliable normalization when using this
technique.
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Author Summary
Stable isotope labeling is used to quantify the rate at which living cells proliferate and die
in humans. It has been central to a number of seminal studies, particularly in viral infec-
tions such as HIV-1, and leukemia. However, different labels (deuterated water or deuter-
ated glucose) yield different estimates for the rate of cell proliferation and loss; this
hampers our understanding and weakens our confidence in this important technique. We
performed in vitro and in vivo experiments as well as a new analysis of existing data to
directly compare the two labels. This reveals that a major source of the discrepancy lies in
the difficulty of assessing deuterated glucose availability. We reconcile published studies
and provide recommendations to avoid this problem in the future.
Introduction
Quantification of lymphocyte kinetics is vital for our understanding of immune cell dynamics
in health and disease. The development [1,2] of stable isotope labeling techniques, using either
deuterium labeled glucose (D2-glucose) or deuterium labeled water (D2O), has enabled the safe
quantification of lymphocyte turnover in humans in vivo. This has provided unprecedented
insight into immunity in healthy individuals, as well as in various conditions, including aging,
viral infection, diabetes and leukemia [3–14].
Despite this breakthrough, estimates of lymphocyte kinetics (i.e. proliferation and loss) are
known to differ up to 10-fold between stable isotope labeling studies, with D2-glucose labeling
consistently yielding higher proliferation and loss rates than D2O labeling [6,8,15–17]. We
have previously shown that short labeling periods can yield higher estimates of proliferation
and loss than long labeling periods [18–20]. In the case of proliferation rate estimates this is
because, with long labeling periods, the label in rapidly turning over cell subpopulations can
saturate leading to an underestimate of the proliferation rate [18,19]. In the case of loss, this is
because the loss rate estimated pertains only to the labeled cell population and the composition
of the labeled cell population will change as the duration of label administration changes [20],
with a stronger bias towards rapidly dividing cells when labelling periods are shorter. Since D2-
glucose labeling protocols usually involve a much shorter labeling period than D2O labeling
protocols, the relationship between the duration of label administration and the estimate of
proliferation and loss explains some of the difference between kinetics obtained using the two
techniques. However, even after correcting for the length of the labeling period, our analysis
here shows that significant discrepancies remain. This raises the concern that there may be fun-
damental differences between D2O labeling and D2-glucose labeling that affect the estimates of
lymphocyte kinetics they produce.
D2-glucose and D2O labeling experiments differ in several aspects, both in the exact experi-
mental procedures as well as in the way the experimental data are translated into the biological
parameters of interest. D2-glucose is typically administered for short periods of time (hours or
days). The pool of blood glucose is small and has a high rate of turnover, so rapid up- and de-
labeling can be achieved [15,16]. Although any part of the glucose molecule could be labeled,
most studies have used 6,6-D2-glucose. During de novo purine and pyrimidine synthesis, the
two non-exchangeable deuteriums on the 6-position are carried over into the 5-position carbon
of the pentose moiety of DNA precursors (as C1 is lost and C6 is redesignated C5) [2]. Deute-
rium enrichment is measured (by mass spectrometry) in the pentose moiety of the DNA of the
cell population of interest. When D2-glucose labeling experiments are conducted in vitro,
enrichment levels in DNA never reach media enrichments but plateau at about 60–75% [2].
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This has been attributed to intracellular dilution of labeled nucleotide triphosphates (NTP) by
pre-formed NTP, by other pentose precursors, and by unlabeled salvage pathway synthesis.
Since the short labeling periods associated with D2-glucose preclude the use of a completely
replaced population to derive product-based estimates of in vivo precursor enrichments, these
plateau tissue culture values have been used to correct for (an assumed similar level of) intracel-
lular dilution in vivo, by applying a scaling factor in the range 0.6–0.75 [19]. Within this manu-
script we refer to this intracellular dilution factor as bg. In addition to adjusting for intracellular
dilution, it is necessary to correct for the label availability, which is estimated by measuring the
label enrichment in glucose in blood plasma at multiple time points.
By contrast D2O is usually administered for several weeks. Intermediary metabolism intro-
duces the deuterium in place of hydrogen in de novo synthesized deoxyribose. To determine
the level of incorporation, mass spectrometric analysis is performed on the deoxyribose moiety
of purine nucleotides [1]. The observed deuterium incorporation in the DNA from the cell
population(s) of interest is normalized to the maximal level of deuterium incorporation that
deoxyribose can attain, which is typically determined in the same individual in a population
with rapid turnover, such as granulocytes, monocytes or thymocytes [8]. This maximum
enrichment attainable is determined by a scaling factor and the level of D2O in the body. The
scaling factor, which is analogous to the intracellular dilution factor bg for D2-glucose, has been
variously referred to as the amplification factor or c [8]. Here, to emphasize analogy to bg, we
refer to it as bw. Deoxyribose contains seven non-exchangable hydrogen atoms, any of which
might potentially be replaced by deuterium [1,21]. Consequently, the maximum level of
enrichment seen in deoxyribose exceeds that seen in plasma and the scaling factor, bw, is
greater than 1; typically bw is in the range 3.5–5.2 [8]. Body water turns over relatively slowly,
so enrichment in the body fluids reaches its maximum and is washed-out from the body more
slowly than D2-glucose. Consequently, there is still considerable de novo DNA labeling long
after the label has been withdrawn. A correction for the level of D2O present in the body fluids
is made by taking the enrichment of blood plasma or urine samples into account [8].
In addition to the methodological differences between D2O and D2-glucose labeling proto-
cols there are differences in the way the compounds are synthesized into deoxyribose [1,19], in
the distribution of water and glucose throughout the body, in the transport of water and glu-
cose into cells, and in the feedback mechanisms that control water and glucose levels. Poten-
tially, some or all of these differences could cause the compounds to give different estimates of
cell kinetics. To date a direct comparison of the two techniques has not been performed. We
sought to address this problem.
We performed stable isotope labeling experiments in vitro and in mice using D2-glucose
and D2O, while keeping every other aspect of the study identical. This showed that, for T cells
in vitro and murine splenocytes and PBMC in vivo, biochemical differences between the com-
pounds do not lead to differences in parameter estimates. Instead, we found that proliferation
rate estimates made using D2-glucose in mice were susceptible to difficulty in estimating rap-
idly fluctuating blood glucose enrichment levels. We therefore hypothesized that the measure-
ment of deuterium enrichment in blood glucose may be an unreliable estimate of the precursor
enrichment. This hypothesis was supported by a new analysis of two published D2-glucose
studies [6,13]. Analogous problems, albeit of a much smaller magnitude, were also found in a
published D2O study [8]. We show that adjusting for these presumed inaccuracies in normali-
zation decreases the proliferation rates estimated in the D2-glucose studies whilst simulta-
neously increasing the proliferation rates from the D2O labeling study, thus bringing these
estimates significantly closer.
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Results
Discrepancy between proliferation rate estimates obtained using D2O
and D2-glucose in humans despite adjusting for the length of the labeling
period
Long labeling periods can lead to an underestimate of cell proliferation rates due to saturation of
label [18]. We therefore investigated whether adjusting for the length of the labeling period
resolves the discrepancy between estimates of lymphocyte proliferation obtained using D2-glu-
cose and D2O labeling. We focused on three published studies in healthy humans where detailed
data were available: a 9 week D2O labeling study [8], a seven-day D2-glucose labeling study [13]
and a one-day D2-glucose labeling study [6] and compared the labeling of total CD4
+ T lympho-
cytes (Methods). We analyzed the data from the seven-day D2-glucose and the 9 week D2O
labeling study using a multi-exponential model [22]. The multi-exponential model (Methods)
consists ofN homogeneous subpopulations; proliferation and death within each subpopulation
is random and occurs at a constant rate and each subpopulation is assumed to be independently
at equilibrium (i.e. proliferation = death). The multi-exponential model allows for saturation of
label in rapidly turning over subpopulations and effectively adjusts for the length of the labeling
period. There were fewer data points available for the one-day D2-glucose study and so the
multi-exponential model could not be used (since it has a relatively large number of free parame-
ters). However, saturation is unlikely to be an issue with such a short labeling period so we used
the alternative, kinetic heterogeneity model [6,20]. The kinetic heterogeneity model is a model
that deals with heterogeneity implicitly by postulating that labeled cells may not be representa-
tive of the whole population and thus the disappearance rate of labeled cells (d) may not be
equal to the proliferation rate of the whole population (p) even for populations at equilibrium
(Methods). The advantage of the kinetic heterogeneity model over the multi-exponential model
is that it has fewer parameters (2 compared with 2N-1 for the multi-exponential model) and, in
the absence of saturation, yields identical estimates of turnover. We confirmed that, even for the
seven-day D2-glucose study, the multi-exponential and kinetic heterogeneity models give identi-
cal proliferation rate estimates, suggesting that, at least for CD4+ T cells, saturation is only a
problem with the long labeling periods associated with D2O. The resulting proliferation rate esti-
mates are shown in Fig 1. The differences between the one-day and seven-day D2-glucose esti-
mates and between the one-day D2-glucose and 9 week D2O labeling estimates were significant
(P = 0.01 and P = 0.003 respectively, two-tailed Mann-Whitney). Thus, although correcting for
the saturation of label in rapidly turning over subpopulations helps to reduce the difference
between the estimates (by increasing the proliferation rate estimates obtained in the 9 week D2O
labeling study) significant discrepancies remain. Strikingly, these discrepancies are not only
apparent in the comparison of D2-glucose and D2O labeling studies but also between the differ-
ent D2-glucose labeling studies. That this is not an artefact of the modeling can be seen by study-
ing the normalized experimental data. In the one-day D2-glucose study, labeling for only one-
day resulted in deuterium enrichment in CD4+ T cells at day 3–5 similar to the enrichment
obtained after 4 days of labeling in the seven-day labeling study (S1 Fig). This basic difference in
data underlies the difference in estimated proliferation rates.
In vitro, no fundamental differences between D2-glucose and D2O
labeling
We sought to directly compare D2O and D2-glucose by labeling an immortalized human T cell
line (Jurkat) in vitro either with D2O or with D2-glucose or with both compounds simulta-
neously. In all cases cells were labeled for seven-days with a seven-day wash-out phase. Data
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were normalized using the conventional strategy. Specifically, we adjusted for the level of label
availability in both the D2-glucose and the D2O labeling experiments based on measured deute-
rium levels in culture media, and we estimated the maximum level of label enrichment that
could be attained by fitting bw in the case of D2O and using a fixed value of bg = 0.65, based on
the maximal end-product enrichment of such cells in vitro, in the case of D2-glucose labeling.
Existing mathematical models, which assume lymphocyte steady state, were adjusted to allow
for a growing cell population (Methods) and fitted to the normalized data. We assumed cell
death in the cultures was negligible. We found that the estimates of proliferation obtained using
D2O (p = 0.50±0.06 d
-1, bw = 3.46±0.27) were similar to those obtained using D2-glucose
(p = 0.52±0.03 d-1), and the difference between the estimates was not significant (P = 0.69, two-
tailed Mann-Whitney), Fig 2, S1 Table, and S2 Fig. We conclude that estimates from in vitroD2-
glucose and D2O labeling are in good agreement and that biochemical differences between D2O
and D2-glucose did not lead to differences in proliferation rate estimates in this experiment.
D2-glucose and D2O labeling experiments in mice: sensitivity to blood
glucose measurements
To compare D2-glucose and D2O labeling in vivo we conducted a seven-day oral labeling study
of mice. For one group of mice both the feed and the drinking water were spiked with D2O to
Fig 1. Total CD4+ T cell proliferation rates estimated from D2-glucose and D2O labeling studies in humans. Each symbol represents a different
individual, horizontal lines represent the median of the estimates. (A) Proliferation rates estimated using the kinetic heterogeneity model. (B) Proliferation
rates estimated after adjusting for saturation (using the multi-exponential model for the nine-week (9w) D2O and seven-day (7d) D2-glucose labeling, and the
kinetic heterogeneity model for one-day (1d) D2-glucose labeling). Although correcting for the saturation of rapidly turning over subpopulations helps to bring
the estimates closer (by increasing the proliferation rate estimates obtained in the nine-week D2O labeling study) significant discrepancies remain.
doi:10.1371/journal.pcbi.1004355.g001
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PLOS Computational Biology | DOI:10.1371/journal.pcbi.1004355 October 5, 2015 5 / 23
an enrichment of 8%; the other group received feed spiked with D2-glucose (comprising ~30%
of glucose intake). Identical chemical composition of feed between groups was maintained by
spiking the feed for D2O-labeled mice with “unlabeled” (normal) glucose and for the glucose-
labeled mice with “unlabeled” water. Food consumption was similar between the groups and
all mice continued to gain weight. Deuterium enrichment was measured in blood plasma,
PBMC, splenocytes, and thymocytes.
All cell types showed a progressive increase in DNA enrichment. Strikingly, the maximum
enrichment in thymocyte DNA in glucose-labeled mice (about 4.5%) exceeded the estimated
precursor (D2-glucose) enrichment, which averaged about 3.3% during the labeling period. Ini-
tially, the raw data were normalized following the conventional approach. That is, both D2-glu-
cose and D2O data were first adjusted for plasma deuterium enrichment. The data were then
scaled to the maximal level of enrichment; for D2O labeling this was determined using the pla-
teau enrichment of a rapidly turning over cell population (thymocytes in this case), and for D2-
glucose by using the in vitro derived constant factor bg = 0.65. The kinetic heterogeneity model
was then fitted to the normalized data. This analysis (Figs 3A and 4) yielded substantially dif-
ferent proliferation rates for the D2O and D2-glucose labeling experiments (Fig 5). Similar (dif-
ferences in) estimates were found using a multi-exponential model.
We were concerned by the large variations in D2-glucose plasma enrichment (Fig 3A) and
the potential impact of mouse diurnal feeding patterns. By contrast, D2O plasma enrichment
showed very little data variability (Fig 4A). In order to improve our estimate of glucose enrich-
ment and reduce sampling error we repeated the D2-glucose arm of the experiment under
identical conditions but with more frequent blood sampling (n = 27 plasma samples in 12 mice
over seven-days) including both day and night sampling (facilitated by a reverse day-night
cycle). As expected, enrichment in DNA from cells (thymocytes, splenocytes, PBMC) reached
very similar values to those from the first experiment; specifically thymus labeling reached a
maximum of about 5.1% with a modeled plateau of 4.9%. As before, large variations in plasma
glucose enrichment were seen (S3 Fig) although these tended to stabilize with time, albeit at
lower levels than in the first 24 hours, suggesting that label may be handled differently in the
early stages of the experiment compared to later. When light-dark patterns were analyzed, a
Fig 2. Proliferation rates of Jurkat cells growing in vitro estimated using D2-glucose and D2O labeling.
Each symbol represents the proliferation rate estimated in a separate experiment, horizontal lines represent
the median of the estimated proliferation rates.
doi:10.1371/journal.pcbi.1004355.g002
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pattern could be discerned in which labeling reached a minimum in the middle of scotophase
in line with previous publications [23] (Fig 6). Importantly, we found similar evidence for a
diurnal pattern in humans that were labeled with D2-glucose [6]. In this study, subjects
received D2-glucose by continuous infusion for 24h but also ate unlabeled low–carbohydrate
meals. The plasma enrichment in these individuals tended to increase during the night (S4
Fig), which is to be expected as the intake of deuterated glucose remained constant whilst the
intake of unlabeled glucose ceased as the individual sleeps (subjects were not woken to receive
nutrition during the night).
We reasoned that variability in the plasma enrichment may make estimation of the D2-glu-
cose availability problematic, we therefore reanalyzed the D2-glucose experiment normalizing
to the estimated plateau enrichment of thymocytes, rather than using the mean plasma enrich-
ment x bg. This reanalysis (Fig 3B) caused a dramatic reduction in proliferation rate estimates
Fig 3. Enrichment curves of D2-glucose labeled mice. Best fits to the fraction of deuterium enrichment in plasma, and the percentage of label enrichment
in the DNA of PBMC, splenocytes and thymocytes after seven-days of D2-glucose labeling. Dots represent individual mice. The end of label administration at
day 7 is marked by a dashed vertical line. (A) Conventional normalization:measurements are normalized to the mean plasma enrichment x bg. (B)
Normalized with respect to thymocytes: thymocytes were used to determine the maximum percentage of labeled DNA that cells could possibly attain
(Methods), and all measured enrichments were scaled to this maximum. The raw data of the % DNA labeled in splenocytes and PBMC is the same in panel A
and B but has been normalized using two different approaches.
doi:10.1371/journal.pcbi.1004355.g003
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from the D2-glucose experiment resulting in good agreement between the proliferation rate
estimates from the D2-glucose and D2O labeling experiments. The average proliferation rate of
PBMC was 0.050 d-1 with D2-glucose and 0.051 d
-1 with D2O; the average proliferation rate of
splenocytes was 0.056 d-1 with D2-glucose and 0.064 d
-1 with D2O (Fig 5). Again, similar esti-
mates were found using a multi-exponential model. In short, when the D2-glucose and D2O
data were analyzed using an identical normalization procedure, the estimates of cell prolifera-
tion were in good agreement; however when conventional normalization approaches (i.e. nor-
malizing to the plasma deuterated glucose level) were used, differences emerged. These
findings suggest that biochemical differences between these deuterium labeled compounds do
not influence lymphocyte proliferation estimates in mice. However, the difficulty of estimating
label availability throughout the course of the experiment may cause discrepancies.
Reanalysis of one-day and 1 week D2-glucose labeling experiments in
humans
Based on these in vitro and in vivo studies we hypothesized that normalization using the
observed D2-glucose enrichment in the blood is problematic as this quantity fluctuates markedly
and shows systematic diurnal variation, making it difficult to assess the label enrichment over
the course of the study. To test this hypothesis we analyzed two published D2-glucose labeling
studies (one-day and seven-day D2-glucose labeling of healthy individuals [6,13] where labeling
in a rapidly turning over population (monocytes) was also available. If the average plasma
Fig 4. Enrichment curves of D2O labeledmice. Best fits to the fraction of deuterium enrichment in plasma
(A) and the percentage of label enrichment in the DNA of thymocytes (B), PBMC (C), and splenocytes (D)
after seven-days of D2O labeling. Thymocytes were used to determine the maximum percentage of labeled
DNA that cells could possibly attain (Methods), and all measured enrichments were scaled to this maximum.
Dots represent individual mice. The end of label administration at day 7 is marked by a dashed vertical line.
doi:10.1371/journal.pcbi.1004355.g004
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enrichment during the labeling period is a good measure of intracellular DNA precursor enrich-
ment, then, if we estimate the plateau enrichment of monocytes (i.e. the maximum label they
can attain) this should be 100%. However if, as we hypothesize, the average D2-glucose enrich-
ment in plasma during the labeling period is a poor surrogate for precursor enrichment, then
the plateau enrichment of the monocytes will be significantly different from 100%. We con-
structed a model of monocyte development in which monocyte progenitors in the bone marrow
proliferate, mature, exit into the blood and from there migrate into tissue to differentiate into
macrophages or dendritic cells (Methods). We fitted this model to the normalized monocyte
data from one-day and seven-day D2-glucose labeling studies and estimated the plateau enrich-
ment of monocytes (Table 1 and S5 Fig). This analysis showed that, for the one-day labeling
study, subjects tended to have a plateau enrichment significantly above 100% whereas for the
seven-day labeling study, mean plateau enrichment was consistent with or slightly lower than
100% (Table 1). Repeating this analysis with a simpler but less physiological model confirmed
these results (“delayed observation”model, Methods). For every model, the plateau enrichment
was significantly higher in the one-day than in the seven-day labeling study (P = 0.048,
P = 0.012, P = 0.012 for the bone marrow, delayed observation and a weighted combination of
both models respectively, two-tailed Mann-Whitney). We conclude that there is evidence that
the mean plasma enrichment may have underestimated the label available to dividing cells dur-
ing the one-day D2-glucose study (and potentially overestimated label availability during the
seven-day study). This conclusion is supported by an analysis of the deuterium enrichment in
blood plasma glucose in the two studies. If we compare the labeling protocol of the one-day and
seven-day D2-glucose studies, we see that the subjects in the one-day labeling study were infused
with approximately twice as much D2-glucose per day as subjects in the seven-day labeling
study. Despite this, the median plasma enrichment measured was only slightly higher in the
one-day labeling study (Fig 7). These findings are consistent with the hypothesis either that the
measured plasma enrichment in the one-day labeling study may have underestimated label
availability (which would in turn have led to an overestimation of the T cell proliferation rate),
or that carbohydrate intake, and thus glucose flux, was higher in subjects in the one-day study.
Fig 5. Proliferation rate estimates from 1 week D2-glucose and D2O labeling in mice. The average
proliferation rate of PBMC and splenocytes, obtained by fitting the kinetic heterogenity model to the data
collected during labeling with D2-glucose with conventional normalization (using 0.65 × plasma AUC, filled
circles), labeling with D2-glucose with normalization to thymocytes (grey-filled circles) and labeling with D2O
with conventional normalization i.e. to thymocytes (open circles). Bars represent 95% confidence intervals;
AUC = area under the curve.
doi:10.1371/journal.pcbi.1004355.g005
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Normalization in D2O labeling studies in humans
These investigations, which reveal a problem with the normalization in D2-glucose labeling
studies, prompted us to also examine the normalization in D2O studies. Again, we focused on
the 9 week D2O labeling study [8] where detailed data were available. In the published study
the data in all T cell subsets were normalized to the maximum enrichment in granulocytes.
Maximum enrichment in granulocytes was estimated based on the measured enrichment in
urine and on an estimate of the intracellular scaling factor bw (c in the notation of the reporting
paper [8]). The factor bw was estimated using a simple model in which granulocytes in the
body were assumed to be a homogeneous population with a single rate of proliferation which
was assumed to be equal to a single death rate. This yielded estimates of the intracellular dilu-
tion bw in the range bw = 3.78–5.15. Since the label in granulocytes comes close to reaching a
maximum, there is little scope for error in this plateau estimation. Nevertheless the model used
is unphysiological. We therefore refitted the data using the more physiological “bone marrow”
model we developed (Methods), in which granulocyte precursors proliferate in the bone mar-
row, followed by a lag period before they enter the blood and then exit the circulation. This
model fitted the data well (S6 Fig) and in most cases resulted in an AICc (a measure of good-
ness of fit penalized by number of parameters [24]) considerably lower than the published
model despite its increased complexity (the published model consistently overestimated the
fraction of labeled cells during the delabeling phase). The estimates of bw from the more physi-
ological bone marrow model were significantly lower than the published estimates (P = 0.01,
two-tailed paired Mann-Whitney, S7 Fig), though the effect is numerically small. This pre-
sumed overestimate of bw in the published study will have caused an underestimate of the pro-
liferation rate in all subpopulations. Correcting for this underestimate leads to a small
Fig 6. Impact of light-dark cycle on plasma glucose enrichment in mice. The fraction of deuterium
enrichment of plasma glucose is plotted against time since the start of label modulo 24 h. Data frommice
housed under reversed day/night condition is translated by 12h so that for all mice 0h represents the start of
light phase (8am for normal conditions, 8pm for reversed day/night conditions). Grey circles represent
measurements from individual mice, the line connects the medians, the points plotted at 24h/0h are
duplicates of the 0h data.
doi:10.1371/journal.pcbi.1004355.g006
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proportional increase in T cell proliferation rate estimates of between 1%-10% (P = 0.0003,
two-tailed paired Mann-Whitney).
Discussion
Several independent lines of evidence indicate that the discrepancy between proliferation rates
estimated with D2O and D2-glucose, once saturation of highly dynamic pools has been
accounted for [18,19], is not explained by a fundamental difference between the compounds
but instead can be explained in part by the difficulty of using deuterium enrichment in plasma
glucose to quantify label availability. Firstly, we find no evidence, either in vitro or in vivo, for a
biochemical difference between D2-glucose and D2O that impacts on cell proliferation rate esti-
mates. Secondly, in mice in vivo, estimates of cell proliferation rates obtained using D2-glucose
and D2O labeling agree if labeled precursor availability during the course of the study is esti-
mated using a rapidly turning over population but not if it is estimated using plasma glucose
enrichments. Thirdly, in humans there is evidence that deuterium enrichment in plasma glu-
cose fluctuates markedly with a predictable increase in enrichment during the night. If the sam-
pling strategy is unbalanced between day and night (or more specifically between post-prandial
and fasting) then the plasma glucose measurements may not reflect label availability through-
out the labeling period. In the case of the one-day labeling study, plasma glucose profiles were
based on 6–8 readings during the labeling period but sampling during the night was avoided to
reduce inconvenience to participants and as a result plasma glucose enrichment during the
whole labeling period may be underestimated. Fourthly, if we compare the labeling protocol of
Table 1. Estimates of the plateau enrichment of monocytes in humans.
Plateau enrichment of monocytes (%)
BM Delayed obs. weighted
1-day D2-glucose C02 98±0 188±0 143±32
C03 110±1 211±0 161±36
C04 100±1 192±0 146±32
C05 109±1 208±0 159±35
C06 144±1 277±0 211±47
C07 131±1 251±0 191±42
C08 146±1 280±0 213±47
C10 153±1 293±0 223±50
MEAN 124±22 237±43 181±32
7-day D2-glucose C2 90±4 105±3 97±6
C3 102±4 120±3 111±7
C4 79±4 92±3 85±5
MEAN 90±12 106±14 98±13
The maximum level of label that monocytes can attain (expressed as a percentage) was estimated for a one-day D2-glucose labeling study (subjects
C02-C10) and a seven-day D2-glucose labeling study (subjects C2–C4). Two different models were considered: the “BM”(bone marrow) model and the
“delayed obs.” (delayed observation) model (Methods). We also calculated the average estimate of the plateau by weighing each ﬁt with the
corresponding Akaike weight [24]; these estimates are given in the column “weighted”. Estimates are shown ± standard deviation (sd). The sd in the
“weighted” column reﬂects model uncertainty (whereas sd for the speciﬁed models assumes the model is correct). For every model the plateau
enrichment was signiﬁcantly higher in the one-day labeling study than in the seven-day labeling study (P = 0.048, P = 0.012, P = 0.012 for the BM,
delayed obs. and weighted model respectively, two-tailed Mann-Whitney). In the one-day labeling study virtually all the plateau estimates were higher than
100% (23/24  100%, 1/24 <100%); for the seven-day labeling study estimates were evenly distributed either side of 100% (4/9  100%, 5/9 < 100%).
doi:10.1371/journal.pcbi.1004355.t001
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the one-day and seven-day D2-glucose studies, we see that the subjects in the one-day labeling
study were infused with approximately twice as much D2-glucose per day as subjects in the
seven-day labeling study. Despite this, the median plasma enrichment measured in the two
experiments did not differ two-fold, again indicating a potential problem in assessing precursor
availability. Finally, when we estimate the plateau enrichment of monocytes in the one-day and
seven-day human D2-glucose labeling studies we find that, although the data have been nor-
malized such that the maximum label incorporation should be 100%, there is evidence in the
one-day labeling study that the maximum incorporation exceeds 100%. Again, this would sug-
gest that the plasma glucose enrichment levels used to normalize the data in the one-day D2-
glucose study underestimated the label availability.
If, as the data summarized above suggest, the label availability has been underestimated in the
one-day human D2-glucose studies then a direct consequence will be that T cell proliferation
rates will have been overestimated. Estimation of the magnitude of these errors is nontrivial. The
difficulty of estimating the plateau enrichment in monocytes after such a short labeling period
means that correction factors for each individual may be unreliable. Instead we focus on correc-
tion factors averaged across the cohort (Table 1). This indicates proliferation rates in the one-
day study have been overestimated by a factor of 1.2–2.4 (16–57%). In contrast, we find little
clear evidence for a problem with the normalization in the seven-day D2-glucose study; if any-
thing there is perhaps a suggestion that label availability may have been overestimated and thus
T cell proliferation underestimated (Table 1). In the case of the 9 week D2O study there is evi-
dence again of a (numerically small) problem in the normalization. Reanalysis of existing 9 week
D2O data with a new model indicates that both naive and memory CD4
+ and CD8+ T cell prolif-
eration rates may have been systematically underestimated by 1–10%. Reducing the T cell prolif-
eration rate estimates from the one-day D2-glucose study and increasing the proliferation rates
from the 9 week D2O study will bring the estimates from the two methods significantly closer.
Fig 7. Deuterium enrichment in plasma glucose in one-day and seven-day D2-glucose labeling
studies of humans. The measured enrichment in plasma glucose in the one-day (grey circles) and seven-
day (black diamonds) D2-glucose labeling studies. The end of the one-day and seven-day labeling periods
are marked by a dashed grey line and a dotted black line respectively. Although subjects in the one-day
labeling experiment (N = 8) received approximately twice as much deuterated glucose per day as subjects in
the seven-day labeling study (N = 4), their median label enrichment is only slightly higher. Median plasma
glucose enrichment in the one-day labeling study = 23%, median plasma glucose enrichment in the seven-
day labeling study = 17%.
doi:10.1371/journal.pcbi.1004355.g007
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There are at least three potential causes for an underestimate of label availability in the one-
day D2-glucose study. Firstly, in the one-day labeling study the sampling of enrichment in plasma
glucose was biased towards daytime (5–7 points during the day, only 1 fasted overnight point, S3
Fig) which may have led to a systematic underestimate of label availability as we have shown that
enrichment increases during the night. In contrast, in the seven-day labeling study, all of the
plasma enrichments were measured after overnight fasting (when plasma enrichment will be at
its peak); thus in the seven-day study the average label availability may be overestimated resulting
in an underestimate of the proliferation rate (consistent with the average plateau enrichment in
monocytes of less than 100%, Table 1). In the case of the seven-day labeling study, this error may
have been relatively small as carbohydrate intake was severely restricted thus reducing fluctua-
tions due to dietary glucose. Secondly, the blood glucose pool is a small pool with a rapid flux,
which is highly dependent upon dietary intake. Although glucose concentrations are very tightly
regulated these regulation mechanisms are unlikely to distinguish between labeled and unlabeled
glucose. Thus whilst total glucose levels are stable, the fraction of enrichment may vary markedly,
particularly following meals. Accurately capturing the mean plasma enrichment with only a few
measurements from a highly variable profile will thus be difficult. Finally, it is routinely assumed
that plasma enrichment will rapidly drop to zero after the end of labeling. However, in both the
one-day and seven-day labeling studies, subjects were not completely fasted (though diet was
restricted) therefore glycogen will have been synthesized fromD2-glucose during this period. Fol-
lowing the end of labeling, this store of “heavy glycogen” would be released, either as D2-glucose
following glycogenolysis or as D2O following glycolysis in the liver. Consequently, label availabil-
ity may be higher than expected following the withdrawal of intravenous D2-glucose. Errors
caused by recycling of label back into the circulation from glycogen will be particularly problem-
atic for short term labeling as the unaccounted for label will be a higher proportion of total label.
Furthermore, because dietary carbohydrate was more tightly restricted in the seven-day labeling
study, postprandial fluctuations and recycling would be reduced compared to the one-day label-
ing study. These factors may explain why a problem with the estimation of label availability is
apparent in the one-day but not the seven-day D2-glucose labeling study. One advantage of long-
term D2O labeling studies compared with short term D2-glucose labeling is that label can be nor-
malized to a rapidly dividing cell population within the same individual. Consequently the level
of label availability is internally controlled. This does however introduce two problems. One is
that the normalization is usually performed using a cell type (typically granulocytes or mono-
cytes) that is different from the cell population studied. Any differences in label availability or
usage between the reference cell population and the studied population will introduce error. Sec-
ondly, the plateau enrichment in the reference population is estimated by modeling and may
therefore be dependent on the choice of model. Why bw, which would be expected to be constant,
varies so markedly between individuals remains unexplained and may hint at further problems
with normalization in the case of D2O. Although the problems associated with normalization
appear to be more severe in the case of D2-glucose, we do not advocate replacing D2-glucose
labeling with D2O labeling as there are many objectives, including labeling of rapidly turning
over populations, evaluating time-courses of appearance and disappearance of labeled cells, and
labeling of cohorts of cells, that cannot be achieved with D2O. Instead, we recommend steps (out-
lined below) to reduce normalization errors.
Based on this work we recommend that, in the case of D2-glucose labeling, plasma glucose
enrichment is measured at frequent intervals, during both day and night as well as following
the withdrawal of label. It is important that sampling times are not all just before or just after
meals (the former would lead to a systematic overestimate of label availability, the latter to a
systematic underestimate). Tightly controlled dietary carbohydrate intake will also help to
reduce fluctuations in plasma enrichment. Important directions for future work with D2-
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glucose include the development of approaches to estimate rapidly fluctuating plasma glucose
enrichments (since continuous blood sampling is not acceptable) and experiments to more
accurately estimate the true in vivo value of bg. In the case of longer term D2O labeling, which
permits normalization to a rapidly turning over subpopulation, we recommend checking for
model dependence in estimates of bw and if necessary using the range of bw to provide a range
of estimated lymphocyte proliferation rates. Additionally, assessing the maximal enrichment
from a range of reference cell populations will highlight whether there are between-cell type
differences in label usage. Future directions for D2O include firstly, investigating why bw,
which would be expected to be constant, varies between individuals and secondly investigating
the impact of the choice of the reference cell population on normalization.
In summary, by combining in vitro, murine and human work with modeling we have dem-
onstrated that biochemical differences between D2-glucose and D2O are not responsible for
discrepancies in proliferation rates obtained with these methods. Instead we conclude that
problems with normalizing the data play an important role. The problems are most acute for
short term D2-glucose labeling where the rapid flux, diurnal variation and potential for label
recycling make accurate estimation of plasma glucose levels difficult.
Methods
Reanalysis of existing T cell studies in humans: impact of length of
labeling
To compare CD4+ T cell enrichment curves of different labeling studies, we calculated the
enrichment level of total CD4+ T cells from a 9 week D2O labeling study [8], a seven-day D2-
glucose labeling study [13] and a one-day D2-glucose labeling study in healthy individuals [6].
The seven-day D2-glucose labeling experiment directly studied total CD4
+ T cells but the 9
week D2O experiment and the one-day D2-glucose experiments studied sorted “naïve” and
“memory” CD4+ T cell subsets (defined as CD27+ CD45RO- and CD45RO+ respectively in [8]
and CD45RO- and CD45RO+ respectively in [6]). For these two studies we used the enrich-
ment data of naïve and memory CD4+ T cell subsets and their relative sizes within the total
CD4+ T cell pool to recalculate the enrichment in total CD4+ T cells (total = naïve + memory).
This approach could not be applied to total CD8+ T cells because there is a considerable frac-
tion of CD27-CD45RO- CD8+ effector T cells, meaning that combining CD27+CD45RO- and
CD45RO+ T cells is not equal to the total CD8+ population.
Multi-exponential model. To adjust for the length of the labeling period we fitted the data
using a multi-exponential model [22,25]. The multi-exponential model assumes N subpopula-
tions, the ith subpopulation has size αi, constant proliferation rate, pi and constant disappear-
ance rate, di. The subpopulations are assumed to be independently at equilibrium and so pi =
di. Fitting is repeated for increasing values of N (starting from N = 1); the value of N which
optimizes the AICc is selected. The multi-exponential model takes the following form:
dA

i
dt
¼ pibUðtÞaiA piA i i ¼ 1 . . .N ð1Þ
Where A is the adenosine in the DNA of the total population, Ai is the labeled adenosine in
the DNA of sub-population i, αi is the size of the i
th subpopulation (relative to the whole popu-
lation), pi is the proliferation rate of the i
th subpopulation, b the intracellular dilution or ampli-
fication factor (b = bw for D2O, b = bg for D2-glucose) and U(t) is the fraction of labeled
precursors in the plasma at time t.
The multi-exponential model allows for saturation of label in rapidly turning over subpopu-
lations but has a larger number of free parameters (2N-1) many of which are poorly
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identifiable, so it could not be used to estimate proliferation in the one-day D2-glucose labeling
study where fewer data points were available. In the case of the one-day D2-glucose labeling
study we therefore used the kinetic heterogeneity model.
Kinetic heterogeneity model. The kinetic heterogeneity model deals with heterogeneity
implicitly by postulating that labeled cells may not be representative of the whole population
and thus the disappearance rate of labeled cells (d) may not be equal to the proliferation rate
of the whole population (p) even for populations at equilibrium. The kinetic heterogeneity
model takes the following form:
dA 
dt
¼ pbUðtÞA d A  ð2Þ
Where A is the total adenosine, A is the labeled adenosine, p is the average proliferation
rate of the whole population, d the disappearance rate of labeled cells, b and U(t) as for the
multi-exponential model.
The advantage of the kinetic heterogeneity model over the multi-exponential model is that
it only has two free parameters both of which are identifiable and, in the absence of saturation,
yields identical estimates of turnover of the whole population to the multi-exponential model
(i.e. p estimated by the kinetic heterogeneity model equals
XN
i¼1
aipi estimated by the multi-
exponential model).
Model fitting. We find the parameters that minimize the difference between the experimen-
tal data and the modeled enrichment (
XN
i¼1
aiA

i=A in the case of the multi-exponential model
and A/A in the case of the kinetic heterogeneity model). Based on conventional normalisation
techniques we ﬁt bw and ﬁx bg = 0.65. Fitting, here and throughout the project, was perfomed
using the pseudorandom algorithm in the modFit function of the FME package in R [26,27].
In vitro labeling
Stable isotope labeling. Jurkat cells were cultured in medium with either deuterated glu-
cose (concentration 20%), deuterated water (concentration 2%), or both for seven-days and
then for an additional seven-days in medium only. Medium was refreshed and cultures were
split on regular intervals to prevent overcrowding in the culture. Cell numbers were determined
using a hemocytometer and corrected for the dilution every time the media was replenished.
DNA was sampled after 0 and 8h and subsequently on days 1, 2, 4, 5, 7, 8, 9, 11, 12 and 14 in
most data sets. In four datasets timepoints 8h, 1d, 5d and 12d were replaced with measurements
on day 3 and 10.
Measurement of deuterium enrichment in DNA. Enrichment of deuterium in DNA was
assayed as previously described [1,19]. Briefly, DNA was extracted and hydrolyzed to deoxyri-
bonucleotides and derivatized to penta-fluoro-triacetate. The deuterium content was analyzed
by gas-chromatography/mass-spectrometry (GC/MS) using an Agilent 5973/6890 GC/MS sys-
tem (Agilent Technologies). The derivative was injected into the GC/MS equipped with a HP-
225 column and measured in SIM mode monitoring ions m/z 435 (M+0), and m/z 436 (M+1;
for D2O labeling) or m/z 437 (M+2; for D2-glucose labeling). From the ratio of ions plasma
deuterium enrichment was calculated by calibration against deoxyadenosine (for D2O labeling)
or deoxyribose (for D2-glucose labeling) standards of known enrichment.
Modeling of in vitro data. We adjusted the previously published kinetic heterogenity
models for D2-glucose [20] and D2O [8] labeling to account for a growing cell population;
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extension to the multi-exponential model did not change our conclusions. We defined a system
of two ODEs, one for the unlabeled population (R) and one for the labeled population (A):
_R ¼ ð1 bUÞpðRþ A  Þ  dR
_A
 ¼ bUpðRþ A  Þ  d A 
during label administration
_R ¼ pðRþ A  Þ  dR
_A
 ¼ d A 
after label administration
where b is the scaling factor for intracellular dilution (b = bg for D2-glucose, b = bw for D2O), U
is the fraction of labeled precursor in the medium, p is the average proliferation rate of cells, d
is the death rate of the unlabeled cells and d is the death rate of the labeled cells. We assume
death is negligible in Jurkat cultures without overcrowding i.e. d = d = 0.
Model fitting. We found the parameters that minimized the difference between the mod-
eled quantity A/(A+R) and the experimental data. Based on conventional normalization
techniques, we fitted bw and fixed bg = 0.65.
In vivo labeling of mice
Ethics statement. Animal work was conducted at the St George's University of London
(SGUL) Biological Research Facility, which is a designated establishment for animal research.
The work in this study was approved by the SGUL Ethical Research Committee, as part of the
process of obtaining the UK Home Office animal project licence (licence number: 70/7490).
Due care was taken at all times to minimize suffering of animals during the experimentation.
Experimental end-points always preceded the onset of any visible signs of suffering.
Stable isotope labeling. C57Bl/6J males, aged ~12 wk, were labeled with either deuterated
(6,6-2H2-) glucose or deuterated water (D2O) for seven-days. For D2-glucose labeling, mice ate
a 30% deuterated glucose liquid feed ad libitum instead of their normal chow for the labeling
period of seven-days; to keep feeding circumstances similar, mice also received normal drink-
ing water. For D2O labeling, mice were given an i.p. boost of 15ml/kg D2O (Cambridge Isotope
Laboratories) in PBS at t = 0 and subsequently drank only 8% D2O; to keep circumstances sim-
ilar, mice ate 8% D2O labeled liquid feed (Nutrison Standard 1.0 kcal/ml) ad libitum instead of
their normal chow for the labeling period of seven-days following a run-in period of seven-
days on a chemically-identical unlabeled liquid diet to ensure a stable metabolic status at the
time of label introduction. For the duration of the experiment, weight of the mice, water con-
sumption, and liquid feed consumption were monitored and recorded.
Sampling. Mice were sacrificed at 8 am on days 0, 1, 2, 3, 4, 7, 8, 10, 15, 21. Thymus and
spleen were obtained by dissection and blood by cardiac puncture. Organs were mechanically dis-
rupted to obtain single-cell suspensions. Blood was spun down to isolate plasma. Plasma was fro-
zen and cells were cryopreserved in liquid nitrogen until further analysis. Prior to hydrolysis and
derivatization for GC-MS analysis, samples with high cell numbers were processed using QiaGen
DNAMini Extraction kit to isolate DNA, and low-yield samples were boiled for an hour.
Measurement of deuterium enrichment in plasma and DNA. Deuterium enrichment in
plasma and DNA from all sampling time points was analyzed by GC/MS. Plasma from D2-glu-
cose labeled mice was derivatized to aldonitrile triacetate (ATA) as previously described. The
derivative was injected into the GC/MS equipped with a HP-225 column (Agilent technologies)
and measured in SIM mode monitoring ions m/z 328 (M+0) and m/z 330 (M+2). Plasma from
D2O labeled mice was derivatized to acetylene (C2H2) as previously described. The derivative
was injected into the GC/MS equipped with a PoraPLOT Q 25x0.32 column (Varian), and
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measured in SIM mode monitoring ions m/z 26 (M+0) and m/z 27 (M+1). From the ratio of
ions plasma deuterium enrichment was calculated by calibration against standard glucose or
water samples of known enrichment. DNA obtained from thymocytes, PBMC and splenocytes
was analyzed as for in vitro labeling (see above).
Modeling of deuterium enrichment in plasma and cell populations in
mice
D2O. There are two normalization steps. A correction for the level of D2O in the plasma,
U(t), and a scaling factor, bw. Plasma enrichment was modeled by fitting a simple label enrich-
ment/decay curve to the cross-sectional plasma enrichment data of all mice from the D2O
labeling group:
UðtÞ ¼ f ð1 edtÞ þ bedt during labeling t  t
UðtÞ ¼ ½f ð1 edtÞ þ bedtedðttÞ after labeling t > t
ð3Þ
as described previously [8], where U(t) represents the fraction of labeled precursor in plasma at
time t (in days), f is the fraction of labeled precursor in the drinking water, τ is the length of the
labeling period, δ is the turnover rate of body water per day, and β is the plasma enrichment
attained after the boost of label by the end of day 0. We incorporated these best ﬁts when ana-
lyzing the enrichment in different cell populations.
Up- and de labeling data of total thymocytes were analyzed as described previously [8], to
estimate the maximum level of label intake that cells could possibly attain. The scaling factor
bw was then chosen such that this maximum level was 100%. Labeling data of PBMC and sple-
nocytes were fitted with the kinetic heterogeneity model [20] (Eq (2)) and subsequently with a
multi-exponential model [18,22] (Eq (1)).
D2-glucose. There are two normalization steps. A correction for the level of D2-glucose in
the plasma, U(t), and a normalization for intracellular dilution, bg. Since glucose is rapidly
turned over rapid up and down labeling is readily achieved so, following the literature, we
approximate the level of D2-glucose in the plasma with a square pulse.
UðtÞ ¼ U t  t
UðtÞ ¼ 0 t > t ð4Þ
Where U is equal to the average label enrichment in the plasma (calculated as the area
under the enrichment-time curve). The intracellular normalization, bg, is set to 0.65 [2].
Labeling data of PBMC and splenocytes were fitted with the kinetic heterogeneity (Eq (2),
[20]) and multi-exponential model (Eq (1), [22,25]).
Impact of light-dark cycle on deuterium enrichment in plasma glucose
Six C57Bl/6J males, ~12weeks old, were housed in normal light/dark conditions; namely light
for 12h from 08:00h to 20:00h and dark for 12h from 20:00h to 08:00h. A further 6 males were
housed in reversed light conditions for 1 week prior to the experiment and then for the dura-
tion of the experiment (dark 08:00h-20:00, light 20:00–08:00h); this was to facilitate sampling
of mice in scotophase during working hours.
All mice were labeled with deuterated (6,6-2H2-) glucose continuously. Mice ate a 30% deu-
terated glucose liquid feed ad libitum instead of their normal chow, mice also received normal
drinking water.
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Modeling human monocyte data
Ethics statement: all human data were derived from existing studies. All data were anonymized
and the original studies were approved by the relevant Ethics Review Boards.
We analyzed label enrichment in the DNA of monocytes from the one-day [6] and seven-
day [13] D2-glucose studies. We constructed two new models, “bone marrow” and “delayed
observation”:
“Bone marrow”model
We constructed a model of monocyte development (Fig 8) in which monocyte progenitors in
the bone marrow proliferate, mature for a fixed time, exit into the blood and from there disap-
pear into tissue (to mature into macrophages).
In the absence of label the system is described by the following set of differential equations:
_MðtÞ ¼ pMðtÞ  εMðtÞ
_BðtÞ ¼ εMðt  DÞ  dBðtÞ
ð5Þ
WhereM(t) is the number of monocyte progenitors in the bone marrow at time t, p is their
proliferation rate and ε their rate of exit into the maturation compartment prior to their exit
into the blood. B(t) is the number of monocytes in peripheral blood, Δ is the time it take a
monocyte progenitor to mature prior to entry into the blood and d is the rate of disappearance
of blood monocytes from the blood into tissue. In the presence of label the system is described
by
_A

M ¼ cbgpUðtÞAM  εA M t  t
_A

M ¼ εA M t > t
_A

B ¼ εA Mðt  DÞ  dA B 8t
ð6Þ
Where AM and AM is total and labeled adenosine in DNA of monocytes in the bone mar-
row, AB and AB is total and labeled adenosine in DNA of monocytes in the peripheral blood.
bg is the intracellular dilution, ψ is the maximal enrichment (will be equal to 1 if the normaliza-
tion is working correctly), τ is the length of the labeling phase, p, ε, Δ and d as above. U(t) is the
label enrichment in the plasma as defined in Eq(4).
Fig 8. Model of monocyte development.Monocyte progenitors in the bone marrow (M(t)) proliferate at rate
p, transit into a maturation compartment at rate ε, where they mature for a fixed time (Δ) before exiting into the
blood compartment (B(t)), from which they disappear at rate d.
doi:10.1371/journal.pcbi.1004355.g008
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We define FM and FB as the fractional label enrichment in marrow and blood monocytes
respectively normalized by intracellular dilution bg (fixed at 0.65) and plasma enrichment:
FMðtÞ ¼
A

MðtÞ
bgAMU
; FBðtÞ ¼
A

B ðtÞ
bgABU
Rearranging Eq (6) and eliminating ε and AM/AB by assuming both blood and marrow
monocytes are independently at equilibrium in Eq (5) gives:
_FM ¼ cp pFM t  t
_FM ¼ pFM t > t
_FB ¼ dFMðt  DÞ  dFB 8t
This system was solved analytically and the theoretical quantity FB fitted to the normalized
monocyte data. Data from all individuals was pooled to avoid overfitting. We fitted p, d, Δ as
population parameters (they each take a single value for the whole population) and ψ as an
individual parameter (each subject has a different value of ψ). So, for example, in the seven-day
D2-glucose study there are 3 subjects and hence 6 free parameters (p, d, Δ, ψ1, ψ2, ψ3).
“Delayed observation”model
We also considered a second model, the “delayed observation”model, which is a simple exten-
sion of the kinetic heterogeneity model which has been described previously [20]. Briefly, the
delayed observation model (like the kinetic heterogeneity model) assumes a heterogeneous
pool but deals with the heterogeneity implicitly [20] (to minimize free parameters). In the
delayed observation model this pool represents the population of bone marrow monocytes and
is therefore observed in the blood with a lag:
_FM ¼ cp d FM t  t
_FM ¼ d FM t > t
FBðtÞ ¼ FMðt  DÞed D 8t
Where FM is the fractional label enrichment in bone marrow monocytes, p is their prolifera-
tion rate, d is the rate of disappearance of labeled monocytes, ψ is the maximal enrichment
and Δ is the lag between an event in the pool and its observation in the blood (FB). The model
was solved analytically and the theoretical quantity FB(t) was fitted to the monocyte data nor-
malized with the intracellular dilution and mean plasma enrichment. Data from all individuals
was pooled. We fitted p, d, Δ as population parameters and ψ as an individual parameter.
Modeling human granulocyte data
We reanalyzed label enrichment in the DNA of granulocytes from the 9 week D2O study to
estimate the scaling factor bw. We used the “bone marrow”model (described above) adjusted
for D2O labeling:
_FM ¼ bwUðtÞp pFM
_FB ¼ dFMðt  DÞ  dFB
Where FM is the fractional label enrichment in bone marrow granulocytes, p is their prolif-
eration rate, d is the rate of disappearance of labeled granulocytes, U(t) is an empirical function
describing the level of enrichment in urine, bw is the scaling factor and Δ is the lag between an
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event in the bone marrow and its observation in the blood (FB). For each of the five subjects
studied (A-E) we used the previously estimated values of β, δ and f [8] to parameterize the
function U(t) (Eq (3)). The theoretical quantity FB(t) was fitted to the raw granulocyte data and
the parameters p, d, Δ and bw were estimated.
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S1 Fig. Normalized CD4+ T cell enrichment in one-day and seven-day D2-glucose labeling
studies of humans. The percentage of labeled DNA in CD4+ T cells as observed in the seven-
day (closed diamonds) and one-day (open circles) D2-glucose-labeling studies [6,13], (A) over
the entire course of the experiment and (B) zoomed in to the first seven days. The end of the
one-day and the seven-day labeling period are marked by the dashed gray and black lines,
respectively. These data have been normalized for both the intracellular dilution (bg) and the
availability of D2-glucose in the plasma. Therefore, everything being equal, we would expect
the fraction of labeled DNA in CD4+ T cells at day 3 to be approximately 3 times higher in the
seven-day labeling experiment than in the one-day labeling experiment (as individuals will
have been labeled for 3 times longer and therefore 3 times as many cells will have divided).
Instead the fraction of labeled cells is very similar in the two experiments.
(PDF)
S2 Fig. Fit to in vitro labeling data. The model fits to the label enrichment in DNA from Jur-
kat cells cultured in medium with either D2-glucose, D2O or both for seven-days and then for
an additional seven-days in medium only. Experiments 1–6 inclusive (first 12 graphs) were
dual labeling experiments, so the cells in D2-glucose expt 1 are the same as the cells in D2O
expt 1, etc. Expts 7 and above are independent datasets with no correspondence between the
D2-glucose and the D2O expts. The proliferation rate estimates are plotted in Fig 2 and listed in
S1 Table.
(PDF)
S3 Fig. Plasma glucose and thymocyte DNA labeling in mice receiving D2-glucose. Deute-
rium labeling in plasma glucose taken both during light and dark phases (open circles, n = 27)
and thymocyte DNA (filled diamonds, dotted line, n = 12) in 12 mice receiving oral feed
labeled with D2-glucose.
(PDF)
S4 Fig. Plasma glucose enrichment in humans. The deuterium enrichment in plasma glucose
in 8 subjects from a one-day D2-glucose labeling study is shown [6]. 0h represents 8am, the
start of the labeling period; the first measurement is taken immediately before the start of label-
ing. All individuals show considerable variations in enrichment over time and in all cases the
enrichment increases over night (between 12h and 24h). The last time point (approx. 24h) was
taken in the morning, immediately prior to breakfast; the one exception to this is C08 who had
breakfast prior to the last measurement. Pearson correlations from 12h-24h: 0.99, 0.40, 0.56,
0.98, 0.97, 1.00, -0.25, 1.00. P = 0.03, two tailed Binary test. The increase in plasma enrichment
during the night is in line with expectation as the infusion of labeled glucose continues whilst
the ingestion of unlabeled glucose in food ceases; this also explains why C08 does not show an
increase in plasma glucose enrichment at the last time point as, for this individual, the mea-
surement was taken immediately after breakfast when unlabeled glucose would be high.
(PDF)
S5 Fig. Fit of the “bone marrow”model to the fraction of DNA labeled in peripheral blood
monocytes in healthy humans. Best fits (black lines) to deuterium enrichment in the DNA of
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peripheral blood monocytes. First row (subjects C2–C4) are subjects in the seven-day D2-glu-
cose study [13]; rows 2–4 (subjects C02-C10) are subjects in the one-day D2-glucose study [6].
Prior in vitro experiments were used to determine the maximum percentage of labeled DNA
that cells could possibly attain giving bg = 0.65, (see Materials and Methods), and all measured
enrichments were normalized by dividing by bg x area under the measured plasma glucose
curve. Each panel represents one subject, the end of label administration is marked by a dashed
vertical line.
(PDF)
S6 Fig. Fit of simple published model and bone marrow model to label in DNA of granulo-
cytes in healthy humans. To normalize the label in DNA of T cells following a 9w D2O label-
ing protocol the maximum level of enrichment in granulocytes was estimated by fitting a
simple mathematical model. Plots show the experimentally measured level of enrichment in
DNA of granulocytes from 5 subjects (A-E) [8], the best fit of the simple, published model (red
dotted line, [8]) and the best fit of the more physiological bone marrow model (solid blue line,
see Materials and Methods). The lag Δ varies between individuals but the estimate of bw is
insensitive to this value.
(PDF)
S7 Fig. Estimates of the intracellular dilution factor bw in healthy humans. The intracellular
dilution factor bw is estimated by fitting a model to the level of enrichment in DNA of granulo-
cytes. We considered two models, the simple published model [8] and a more physiological
model (Materials & Methods). The fits of the models to the data are shown in S5 Fig, the result-
ing estimates of bw are shown here. The 95% confidence intervals of the estimates are also plot-
ted but are too small to be seen. The reanalysis results in a small but statistically significant
decrease in bw. If T cell proliferation rates are estimated with this refined value of bw then they
increase significantly (P = 0.0003) but again the difference is numerically small (1–10%).
(PDF)
S1 Table. Estimates of proliferation rate from in vitroD2-glucose and D2O labeling. Experi-
ments 1–6 inclusive were dual labeling experiments, so the cells in D2-glucose experiment 1 are
the same as the cells in D2O experiment 1, etc. Experiments 7 and above are independent data-
sets with no correspondence between the D2-glucose and the D2O experiments. Estimates are
shown with 95% confidence intervals. These proliferation rate estimates are plotted in Fig 2,
the experimental data and model fits are plotted in S2 Fig.
(PDF)
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